Key result
Review updates benefits and harms of short DAPT after PCI with newer-generation DES.
Why the study?
Evidence from randomized clinical trials of shorter DAPT regimens after PCI with newer-generation DES is emerging across diverse patient populations, requiring an update on their benefits and harms.
Does short duration dual antiplatelet therapy improve outcomes compared to standard duration in patients undergoing percutaneous coronary intervention with newer-generation drug-eluting stents?
Does short duration dual antiplatelet therapy improve outcomes compared to standard duration in patients undergoing percutaneous coronary intervention with newer-generation drug-eluting stents?
This review summarizes emerging evidence on the benefits and harms of shorter DAPT regimens following PCI with newer-generation DES across heterogeneous patient populations.
May inform shorter DAPT post-PCI with newer DES in select patients; leaves open optimal duration by bleeding-thrombosis risk.
Current guidelines recommend a duration of dual antiplatelet therapy (DAPT) with aspirin and oral P2Y<inf>12</inf> receptor inhibitors following percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) of 6 months for most patients with stable coronary disease and of 12 months for most patients with acute coronary syndromes. Large evidence from randomised clinical trials of shorter DAPT regimens after PCI with newer-generation DES is now emerging in heterogenous patient population not selected on the basis of high bleeding risk as well as in patients at high bleeding risk. The scope of this review is to provide an update on the benefits and harms of these short DAPT regimens and to discuss future directions in DAPT strategies after PCI with newer generation DES.
No takes yet. Share an insight, caveat, or question.
Roccasalva et al. (2020) conducted a review in Percutaneous coronary intervention with drug-eluting stents. Short dual antiplatelet therapy (DAPT) regimens was evaluated. This review provides an update on the benefits and harms of short dual antiplatelet therapy regimens after percutaneous coronary intervention with newer-generation drug-eluting stents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: